Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
78
resultados
Última actualización
01/05/2026 [06:46:00]
Resultados 25 a 50 de 78
Resumen de: US20260104330A1
The present invention discloses a leukemia cell separation and extraction device, comprising a sampling tube and a filtration assembly. Top end of inner wall of sampling tube is equipped with multiple limit blocks, while filtration assembly includes a retaining ring installed at top opening of the sampling tube, with one side contacting the limit blocks. The bottom end of inner wall of retaining ring is connected to an air duct via multiple connecting plates, with membranes between each plate. Main drainage rods, inclined and circumferentially arranged, connect the air duct's outer wall to the retaining ring's inner wall, with zigzag secondary drainage rods between them. One end of the retaining ring is attached to a push plate, and a collecting assembly is mounted on the air duct. This configuration allows for efficient plasma extraction from blood samples, retaining blood cells in the original container and enhancing separation efficiency.
Resumen de: WO2026078266A1
The present invention refers to anti-BCMA specific single domain antibodies, and their use in chimeric antigen receptor cells, specifically T cells, which are of use in the treatment of cancer characterized by an increase in cells expressing BCMA, in particular multiple myeloma.
Resumen de: WO2026078067A1
The present disclosure relates to human/cynomolgus cross-reactive antibody arms that bind specifically to FcRH5, which preferentially bind to membrane-bound FcRH5 (isoform c) and which do not cross-react with other FcRH family members. The present disclosure relates to bispecific antibodies which bind to human FcRH5 using the anti-FcRH5 arms described herein and bind to human CD28. The bispecific antibodies of the disclosure provide FcRH5-dependent costimulatory signal to T cells, even in the presence of soluble FcRH5, enhancing T cell mediated anti-tumor immunity against FcRH5-expressing cancers such as multiple myeloma.
Resumen de: WO2026078200A1
This invention relates to recombinant mammalian cells and their use in treating cancer. The present invention specifically relates to the co-expression of an adapter CAR and a conventional CAR in CAR T cells and the use of these cells in treating lymphoma. The invention also relates to pharmaceutical compositions comprising such recombinant mammalian cells, as well as their uses in cancer therapy.
Resumen de: US20260102387A1
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, solvate or isomers and mixtures thereof. The invention further relates to a process for the stereoselective preparation of such compounds. The compound of formula (I) can be used as a medicament, in particular for inhibiting coronin 1 expression in the induction of immunosuppression or in the treatment and/or prevention of a disease or disorder selected from the group consisting of transplant rejection, autoimmune diseases, inflammatory diseases, infectious diseases, and lymphoproliferative disorders. The present invention further relates to a vector comprising a coronin 1 promoter element, wherein in a vertebrate genome, said coronin 1 promoter element starts directly upstream from a transcription starting site (TSS) of a coronin 1 gene and spans a sequence stretch of at least about 700 bp in said genome. The present invention further relates to a method using said vector for identifying immunomodulatory compounds that alter the coronin 1 promoter activity. The present invention further relates to BRD3 as an upstream target responsible for driving the coronin-1 expression and activity in immune cells, and relates to compounds, in particular compound of formula (I), that selectively target bromodomains of BRD3 and thereby deplete coronin 1 levels.
Resumen de: AU2024353668A1
Described herein are Casitas B-lineage lymphoma (Cbl) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or condition associated with Cbl-b activity, such as cancers.
Resumen de: AU2024358317A1
Provided are an anti-BCMA single-domain antibody, and a preparation method therefor and the use thereof. Specifically, provided is a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can thoroughly specifically target BCMA-positive cells, and can be applied to the detection of BCMA expression in bone marrow cells of MM patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating BCMA-target-related diseases (such as multiple myeloma, B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma and Hodgkin's lymphoma); or a BCMA protein detection kit, etc. The single-domain antibody has a stable structure, a small molecular size, is easily recombinantly expressed and has a low production cost, can be used alone or as a drug delivery system to carry relevant drugs, and has very wide prospects and important significance in fields such as drug application and clinical diagnosis.
Resumen de: WO2026078018A1
The present invention refers to anti-CD33 specific single domain antibodies, and their use in chimeric antigen receptor cells, mainly T cells, which are of use in the treatment of cancer characterized by an increase in cells expressing CD33, in particular acute myeloid leukemia.
Resumen de: US20260103515A1
The present disclosure relates to doses and dosing regimens of a bispecific antibody that binds myeloid cell surface antigen CD33, and the Vδ2 chain of the human Vγ9Vδ2 T cell receptor; to pharmaceutical compositions comprising said antibodies, as well as methods of administration of the referred doses, and to the use of said antibodies in the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Neoplasms (MDS), in particular Relapsed or Refractory (R/R) AML or MDS.
Resumen de: US20260102397A1
The present invention relates to a pharmaceutical composition for the treatment of leukemia comprising an FMS-like tyrosine kinase-3 (FLT3) inhibitor and a pharmaceutically acceptable excipient.
Resumen de: US20260102374A1
Methods of treating bacterial infection in immunocompromised subjects and subjects with one or more underlying malignancies include administering a combination of meropenem and vaborbactam to the subject. Suitable subjects to be treated can include a subject with a history of ongoing leukemia or lymphoma, a subject that has had an organ transplant, stem cell transplant, bone marrow transplant, or splenectomy, a subject receiving immunosuppressive medications, a subject receiving bone marrow ablative chemotherapy, a subject with neutropenia and subject suffering from or having suffered from a malignancy.
Resumen de: AU2024380949A1
The present invention relates to a method of treating an anaplastic lymphoma kinase (ALK) fusion-positive solid tumour or central nervous system tumour, comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject is aged <18 years.
Resumen de: AU2024366453A1
The present invention relates to methods of treating previously untreated diffuse Large B-Cell Lymphoma (DLBCL) defined as high risk by Circulating Tumor DNA (ctDNA), by administering glofitamab and in combination with chemotherapy.
Resumen de: US20260102490A1
Embodiments disclosed herein relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of BCMA×GPRC5D×CD3 trispecific antibody or trispecific binding fragment thereof and an anti-CD38 antibody, to the subject to the subject to treat the multiple myeloma.
Resumen de: US20260103537A1
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
Resumen de: US20260103445A1
The present invention relates to compositions comprising an RXR agonist, an RAR agonist, or a dual RXR/RAR agonist. The present invention further relates to methods of using the agonist compositions for treating or preventing dementia and cancer. In some embodiments, the dementia comprises Alzheimer's disease. In some embodiments, the cancer comprises leukemia.
Resumen de: US20260103455A1
The present disclosure provides compounds of Formula (I), Formula (II) and Formula (III) which are useful as inhibitors of ULK3 and methods of using the same to treat cancers, such as ULK-associated cancers, for example multiple myeloma and breast cancer.
Resumen de: AU2024350024A1
Provided herein are systems, kits, and methods for generating an enriched T cell population from an initial peripheral blood mononuclear cell (PBMC) population using at least two types of cell-binding reagents: (e.g., particles conjugated to CD32, CD19, CD244, or CD25 binding agents), where the enriched T cell population is: i) enriched for desired T-cells (e.g., early memory T cells and naïve T cells), and ii) depleted in normal and malignant non-desired cells selected from: CD25hi regulatory T-cells (Tregs), CD25hi CLL cells, CD244 T-cells, CD32+ monocytes, CD32+ myeloid leukemia cells, CD32 basophils, CD19+ and/or CD32+ B cells, CD244+ natural killer (NK) cells, and myeloid cells). In certain embodiments, the enriched T cell populations are used for generating a population of chimeric antigen receptor (CAR) T-cells, T-cell receptor-engineered T cells, or Tumor-infiltrating T lymphocyte (ITL) products.
Resumen de: AU2024369003A1
The present application relates to use of a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) in rare anemia. Specifically disclosed in the present application is use of certain hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) in the treatment of anemia of myelodysplastic syndromes (MDS anemia), beta-thalassemia (β-thalassemia), and/or sickle cell disease (sickle cell anemia, SCD anemia).
Resumen de: AU2024352563A1
The invention relates to the field of leukemia/lymphoma diagnosis, more specifically to the detection of MRD in bone marrow, blood and other fluids and tissues from patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (T-ALL/T-LBL). Provided is a reagent composition for the cytometric detection of minimal residual disease (MRD) in T-ALL and/or T-LBL, the reagent composition comprising a panel of at least four antibodies conjugated to a detectable label, the panel comprising antibodies against markers NKp80, CD16, cyCD3 and smCD3.
Resumen de: EP4726031A1
This disclosure discloses a CLL1-CAR-T cell, as well as their preparation methods and applications. Specifically, it reveals CLL1-CAR-T cell that contain a chimeric antigen receptor, which comprises a single-domain antibody, a hinge region, a transmembrane region, and an intracellular signaling region. The amino acid sequence of the single-domain antibody corresponds to positions 22-150 of SEQ ID No.1. The CLL1-VHH-1 CAR-T cells of this disclosure can effectively secrete the T-cell-specific effector molecule IFN-γ, specifically and efficiently kill CLL1+ target cells, and exhibit favorable in vivo anti-tumor activity. They not only significantly inhibit the proliferation of tumor cells in mice but also markedly prolong the survival time of mice. The CLL1-VHH-1 CAR-T cells of this disclosure demonstrate excellent anti-tumor capabilities and can be used for immunotherapy of diseases related to the CLL1 target, such as acute myeloid leukemia, presenting broad prospects for clinical applications.
Resumen de: WO2024254455A1
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell- like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).
Resumen de: WO2026074086A1
The present invention relates to cells expressing chimeric antigen receptors against BCMA and a glutamine transporter, and uses thereof in the treatment of cancer or autoimmune diseases. The invention also relates to a method for the prognosis of multiple myeloma in a subject.
Resumen de: WO2026076363A1
Provided herein is the use of particular dose levels or amounts of certain pyruvate kinase activators or pharmaceutically acceptable salts or compositions thereof, for treating anemia associated with low risk MDS, lower risk MDS and/or intermediate risk MDS (collectively, LRMDS) and other conditions.
Nº publicación: AU2025316407A1 09/04/2026
Solicitante:
JANSSEN BIOTECH INC
Resumen de: AU2025316407A1
The present disclosure is directed to methods of treating, for example, newly diagnosed multiple myeloma.
BOPI
Sede Electrónica
